Skip to Content

Cisatracurium Besylate

Class: Neuromuscular Blocking Agents
VA Class: MS300
Chemical Name: [1R-[1α,2α(1′R*,2′R*)]]-2,2′-[1,5-pentanediyl-bis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-isoquinolinium dibenzenesulfonate
Molecular Formula: C65H82N2O18S2
CAS Number: 96946-42-8
Brands: Nimbex

Warning(s)

  • Should be administered only by adequately trained clinicians experienced in the use and complications of neuromuscular blocking agents.1

Introduction

Nondepolarizing neuromuscular blocking agent (benzylisoquinolone); isomer of atracurium.1 3 5 6 7 11 14 15 19 20

Uses for Cisatracurium Besylate

Skeletal Muscle Relaxation

Production of skeletal muscle relaxation during surgery after general anesthesia has been induced.1 5 11 20 21

Facilitation of endotracheal intubation; however, a neuromuscular blocking agent with a rapid onset of action (e.g., succinylcholine, rocuronium) generally preferred in emergency situations when rapid intubation is required.21 424 Cisatracurium is not recommended for rapid sequence intubation because of its intermediate onset of action.1 5 11 21 22

Also has been used to facilitate mechanical ventilation in the ICU.1 2 3 5 8 10 14 21 45 46 Has been given as a continuous IV infusion for up to 6 days in this setting.1 Whenever neuromuscular blocking agents are used in the ICU, consider benefits versus risks of such therapy and assess patients frequently to determine need for continued paralysis.1 21 (See Intensive Care Setting under Cautions.)

Compared with other neuromuscular blocking agents, cisatracurium has an intermediate onset and duration of action; exhibits minimal, if any, cardiovascular effects; and causes less histamine release than atracurium.1 3 20 21 Because elimination is not dependent on renal or hepatic pathways, may be particularly useful in patients with hepatic or renal dysfunction.1 3 20 21

Cisatracurium Besylate Dosage and Administration

General

  • Facilities and personnel necessary for intubation, administration of oxygen, and respiratory support should be immediately available.1 359 424 (See Boxed Warning.)

  • Adjust dosage carefully according to individual requirements and response.1 21

  • Assess neuromuscular blockade and recovery with a peripheral nerve stimulator to accurately monitor the degree of muscle relaxation, determine need for additional doses, and minimize possibility of overdosage.1 3 21 48 (See Administration Precautions under Cautions.)

  • To avoid patient distress, administer in conjunction with adequate analgesia and sedation, and only after unconsciousness has been induced.1 3 21 359 423 424

  • A reversal agent should be readily available in the event of a failed intubation or to accelerate neuromuscular recovery after surgery.1 21 359 (See Reversal of Neuromuscular Blockade under Dosage and Administration.)

Reversal of Neuromuscular Blockade

  • To reverse neuromuscular blockade, administer a cholinesterase inhibitor (e.g., neostigmine, pyridostigmine, edrophonium) in conjunction with an anticholinergic agent such as atropine or glycopyrrolate to block adverse muscarinic effects of the cholinesterase inhibitor.1 21 Time to recovery of neuromuscular function is dependent upon strength of neuromuscular blockade at time of reversal.1

  • To minimize risk of residual neuromuscular blockade, attempt reversal only after some degree of spontaneous recovery has occurred; monitor patients closely until adequate recovery of normal neuromuscular function is assured (i.e., ability to maintain satisfactory ventilation and a patent airway).1 21 355 356 357 358

Administration

Administer IV only.1

Commercially available 20-mL vial containing 10 mg/mL intended for ICU use only.1

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Consult specialized references for specific procedures and techniques of administration.

Administer initial (intubating) dose by rapid IV injection; administer maintenance doses by intermittent IV injection or continuous IV infusion.1

Rate of spontaneous recovery after discontinuance of a maintenance infusion is comparable to that following administration of a single IV injection.1

Continuous IV infusions have been administered for up to 3 hours without evidence of cumulative neuromuscular blocking effects; such administration has no effect on duration of blockade, provided partial recovery is allowed to occur between doses.1 48

Dilution

For continuous IV infusion, dilute to desired concentration (e.g., 0.1–0.4 mg/mL) in a compatible IV solution.1 48 (See Storage and also Compatibility, under Stability.)

Rate of Administration

Direct IV injection: Usually administer over 5–10 seconds.1

Continuous IV infusion: Individualize infusion rate based on patient requirements and response to peripheral nerve stimulation.1 48 (See Tables 1 and 2 for recommended rates of infusion.)1 Accurate dosage is best achieved using a precision infusion device.1 359

Table 1. Infusion Rates Required to Deliver Selected Dosages of Cisatracurium from Solutions Containing 0.1 mg/mL of the Drug1

 

Drug Delivery Rate (mcg/kg per minute)

 

1

1.5

2

3

5

Weight (kg)

Infusion Delivery Rate (mL/hr)

10

6

9

12

18

30

45

27

41

54

81

135

70

42

63

84

126

210

100

60

90

120

180

300

Table 2. Infusion Rates Required to Deliver Selected Dosages of Cisatracurium from Solutions Containing 0.4 mg/mL of the Drug1

 

Drug Delivery Rate (mcg/kg per minute)

 

1

1.5

2

3

5

Weight (kg)

Infusion Delivery Rate (mL/hr)

10

1.5

2.3

3

4.5

7.5

45

6.8

10.1

13.5

20.3

33.8

70

10.5

15.8

21

31.5

52.5

100

15

22.5

30

45

75

Dosage

Available as cisatracurium besylate; dosage expressed in terms of cisatracurium.1

Pediatric Patients

Skeletal Muscle Relaxation
Initial (Intubating) Dose
IV

Infants 1–23 months of age: 0.15 mg/kg when used concomitantly with halothane or opiate anesthesia.1 Generally produces maximum neuromuscular blockade in about 2 minutes.1 (See Onset and also Duration under Pharmacokinetics.)

Children 2–12 years of age: 0.1–0.15 mg/kg when used concomitantly with halothane or opiate anesthesia.1 A dose of 0.1 or 0.15 mg/kg generally produces maximum neuromuscular blockade in about 2.8 or 3 minutes, respectively.1 (See Onset and also Duration under Pharmacokinetics.)

Adolescents ≥13 years of age: Manufacturer makes no specific dosage recommendations.1 48

Maintenance Dosage During Prolonged Surgical Procedures
Continuous IV Infusion

After initial intubating dose is administered, children ≥2 years of age may receive continuous IV infusion of cisatracurium for maintenance of neuromuscular blockade; individualize infusion rate based on patient response to peripheral nerve stimulation.1 48

Initiate continuous IV infusion only after early spontaneous recovery from initial IV dose is evident.1

Initially, 3 mcg/kg per minute may be necessary to rapidly counteract spontaneous recovery from neuromuscular blockade.1 Thereafter, 1–2 mcg/kg per minute generally sufficient to maintain 89–99% neuromuscular blockade in most pediatric patients receiving balanced anesthesia.1

Consider reducing infusion rate by up to 30–40% if steady-state anesthesia has been induced with enflurane or isoflurane; greater reductions may be required with prolonged durations of enflurane or isoflurane administration.1 (See Specific Drugs under Interactions.)

Adults

Skeletal Muscle Relaxation
Initial (Intubating) Dose
IV

0.15 or 0.2 mg/kg depending on desired time to intubation and duration of procedure.1

Following a dose of 0.15 or 0.2 mg/kg, good to excellent intubating conditions generally occur within 2 or 1.5 minutes, respectively.1 (See Onset and also Duration under Pharmacokinetics.)

Maintenance Dosage During Prolonged Surgical Procedures
Intermittent IV Injection

0.03 mg/kg as needed.1

First maintenance dose generally required within 40–50 or 50–60 minutes following initial dose of 0.15 or 0.2 mg/kg, respectively.1 5

Each 0.03-mg/kg dose provides approximately 20 minutes of additional neuromuscular blockade.1 For shorter or longer durations of action, administer smaller or larger doses.1

Less frequent or lower doses of cisatracurium may be necessary when administered concomitantly with enflurane or isoflurane anesthesia during prolonged surgical procedures.1 No dosage adjustment appears to be necessary when cisatracurium is administered shortly (e.g., within 15–30 minutes) after initiation of the inhalation anesthetic.1 (See Specific Drugs under Interactions.)

Continuous IV Infusion

After initial intubating dose is administered, may initiate continuous IV infusion to maintain neuromuscular blockade during prolonged procedures; initiate infusion only after early spontaneous recovery from IV dose is evident.1

Individualize infusion rates based on patient response to peripheral nerve stimulation.1

Initially, 3 mcg/kg per minute may be necessary to rapidly counteract spontaneous recovery from neuromuscular blockade.1 Thereafter, 1–2 mcg/kg per minute generally sufficient to maintain 89–99% neuromuscular blockade in most patients receiving balanced anesthesia.1

Consider reducing infusion rate by up to 30–40% if steady-state anesthesia has been induced with enflurane or isoflurane; greater reductions may be required with prolonged durations of enflurane or isoflurane administration.1 (See Specific Drugs under Interactions.)

Maintenance Dosage in ICU
Continuous IV Infusion

To support mechanical ventilation in the ICU, average infusion rates of approximately 3 mcg/kg per minute have been required.1 However, dosage requirements may vary widely among patients and may increase or decrease with time.1

Monitor degree of neuromuscular blockade with a peripheral nerve stimulator.1 Do not administer additional doses before there is a definite response to nerve stimulation.1

Following recovery from neuromuscular blockade, administration of an IV (“bolus”) dose may be necessary to reestablish neuromuscular blockade prior to reinstitution of the infusion.1

Use for >6 days during mechanical ventilation in the ICU has not been evaluated in clinical studies.1 (See Intensive Care Setting under Cautions.)

Special Populations

Renal Impairment

Onset of complete neuromuscular blockade may be slower; it may be necessary to extend the interval between administration of cisatracurium and the intubation attempt.1 16

Geriatric Patients

Onset of complete neuromuscular blockade may be slower; it may be necessary to extend the interval between administration of cisatracurium and the intubation attempt.1 16

Burn Patients

Substantially increased doses may be required due to development of resistance.1 However, no clinical studies to date in these patients, and no specific doses are recommended.1 (See Burn Patients under Cautions and also see Distribution: Special Populations, under Pharmacokinetics.)

Cardiopulmonary Bypass Patients with Induced Hypothermia

Infusion rate of atracurium required to maintain adequate surgical relaxation during hypothermia (i.e., 25–28°C) is approximately 50% of the infusion rate necessary in normothermic patients; a similar reduction in the infusion rate of cisatracurium may be expected.1 15

Other Populations

Patients in whom potentiation of neuromuscular blockade or difficulties with reversal of blockade may occur (e.g., neuromuscular disease, carcinomatosis): A dose of ≤0.02 mg/kg is recommended along with monitoring of subsequent dosage adjustments.1 (See Neuromuscular Diseases and also see Carcinomatosis, under Cautions.)

Cautions for Cisatracurium Besylate

Contraindications

  • Known hypersensitivity to cisatracurium or any of its components.1

  • Multiple-dose vials containing benzyl alcohol contraindicated in premature infants.1 (See Pediatric Use under Cautions.)

Warnings/Precautions

Warnings

Administration Precautions

Because of the potential for severely compromised respiratory function and other complications, take special precautions during administration.1 21 23 359 424 (See Boxed Warning and also see General under Dosage and Administration.)

Sensitivity Reactions

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, reported rarely.1 Potential for cross-sensitivity with other neuromuscular blocking agents (both depolarizing and nondepolarizing).1

Take appropriate precautions; emergency treatment for anaphylaxis should be immediately available.1

General Precautions

Neuromuscular Diseases

Possible exaggerated neuromuscular blockade in patients with neuromuscular diseases (e.g., myasthenia gravis, Eaton-Lambert syndrome).1 23

Monitor degree of neuromuscular blockade with a peripheral nerve stimulator; dosage reduction is recommended.1 (See Other Populations under Dosage and Administration.)

Burn Patients

Resistance to nondepolarizing neuromuscular blocking agents33 34 35 37 38 can develop in burn patients, particularly those with burns over 25–30% or more of body surface area.1 33 34 35 36 37 38 39

Resistance generally becomes apparent ≥1 week after the burn,33 34 35 36 37 38 39 peaks ≥2 weeks after the burn,34 35 36 38 persists for several months or longer,34 36 and decreases gradually with healing.33 34 36 38

Consider possible need for substantially increased doses.1

Intensive Care Setting

Possible prolonged paralysis and/or muscle weakness with long-term administration of neuromuscular blocking agents in the ICU.3 20

Continuous monitoring of neuromuscular transmission recommended during neuromuscular blocking agent therapy in intensive care setting.1 3 21 48 Do not administer additional doses before there is a definite response to nerve stimulation tests.1 If no response is elicited, discontinue administration until a response returns.1

Seizures reported rarely with atracurium in patients with predisposing factors (e.g., head trauma, cerebral edema, hypoxic encephalopathy, viral encephalitis, uremia) receiving continuous IV infusions for facilitation of mechanical ventilation in the ICU.1 20 Unclear whether laudanosine (metabolite of atracurium and cisatracurium) contributes to CNS excitation (see Metabolism under Pharmacokinetics).1

Cardiovascular Effects

No clinically important effects on heart rate at recommended doses and exhibits minimal, if any, cardiovascular effects;1 3 16 18 20 therefore, will not counteract the bradycardia induced by many anesthetic agents or by vagal stimulation.1

Electrolyte Disturbances

Acid-base and/or serum electrolyte abnormalities may potentiate or antagonize action of cisatracurium.1

Hemiparesis and Paraparesis

Resistance to therapy may develop in the affected limbs of patients with hemiparesis or paraparesis.1

Monitor neuromuscular transmission in a nonparetic limb to avoid inaccurate dosing.1

Malignant Hyperthermia

Malignant hyperthermia is rarely associated with use of neuromuscular blocking agents and/or potent inhalation anesthetics.1 20 Cisatracurium has not been studied in patients with increased susceptibility to malignant hyperthermia.1 Be vigilant for its possible development and prepared for its management in any patient undergoing general anesthesia.1

Carcinomatosis

Possible exaggerated neuromuscular blockade in patients with carcinomatosis.1 Carefully monitor the degree of neuromuscular blockade with a peripheral nerve stimulator; dosage reduction is recommended.1 (See Other Populations under Dosage and Administration.)

Specific Populations

Pregnancy

Category B.1

Not known whether use during labor, delivery, or cesarean section has effects on the fetus.1

Lactation

Not known whether cisatracurium is distributed into milk.1 Caution advised if used in nursing women.1

Pediatric Use

Safety and efficacy not established in neonates (<1 month of age).1

Tracheal intubation was facilitated more reliably in children 1–4 years of age when used in conjunction with halothane than when used in conjunction with opiates and nitrous oxide.1

Large amounts of benzyl alcohol (i.e., 100–400 mg/kg daily) have been associated with toxicity in infants;1 24 25 26 27 28 29 each mL of cisatracurium besylate injection in multiple-dose vials contains 9 mg of benzyl alcohol.1 (See Contraindications under Cautions.)

Geriatric Use

No overall differences in safety and efficacy relative to younger adults, but increased sensitivity of some older patients cannot be ruled out.1

Minor alterations in pharmacokinetics, but no substantial differences in recovery profile.1 (See Pharmacokinetics.)

Hepatic Impairment

Minor alterations in pharmacokinetics, but no substantial differences in recovery profile.1 Concentration of metabolites may be increased after prolonged administration in patients with hepatic disease.1 (See Pharmacokinetics.)

Renal Impairment

Pharmacokinetic/pharmacodynamic profile similar to that in healthy adults;1 concentration of metabolites may be increased after prolonged administration in patients with renal failure.1 (See Pharmacokinetics.)

Common Adverse Effects

Surgical patients: None with incidence >1% in clinical trials.1

Intensive care patients: Prolonged recovery from neuromuscular blockade.1

Interactions for Cisatracurium Besylate

Specific Drugs

Drug

Interaction

Comments

Anesthetics, general (enflurane, isoflurane)

Increased potency and prolonged duration of neuromuscular blockade1 21 32

Reduced cisatracurium dose and/or infusion rate may be necessary1 32

Anesthetics, local

Possible increased neuromuscular blockade1 3

Anticonvulsants (carbamazepine, phenytoin)

Possible resistance to cisatracurium in patients receiving long-term phenytoin or carbamazepine therapy1 3 30

Higher cisatracurium infusion rates may be necessary1 30

Anti-infectives (aminoglycosides, bacitracin, clindamycin, lincomycin, polymyxins, tetracyclines)

Possible increased neuromuscular blockade1 3

Lithium

Possible increased neuromuscular blockade1 3

Magnesium salts

Increased neuromuscular blockade1 3 40

Use with caution; reduced cisatracurium dosage may be necessary40

Neuromuscular blocking agents, nondepolarizing

Potency and duration of nondepolarizing neuromuscular blocking agents may be altered by concurrent or prior administration of other nondepolarizing agents31

Vecuronium, pancuronium, or atracurium has been administered safely following various degrees of recovery from cisatracurium-induced blockade1

Procainamide

Possible increased neuromuscular blockade1 3

Propofol

No apparent effect on duration of neuromuscular blockade1

No dosage adjustment required1

Quinidine

Possible increased neuromuscular blockade1 3

Succinylcholine

Prior administration of succinylcholine may decrease time to maximum neuromuscular blockade with cisatracurium by about 2 minutes1

Prior administration of succinylcholine does not appear to alter duration of blockade induced by intermittent injections of cisatracurium; prior administration resulted in no change or only slight increase in cisatracurium infusion requirements1

Cisatracurium has been used safely following various degrees of recovery from succinylcholine-induced neuromuscular blockade1

Cisatracurium Besylate Pharmacokinetics

Absorption

Bioavailability

Poorly absorbed from GI tract.23

Onset

Intermediate onset of action.1 5 Generally, time to maximum neuromuscular blockade decreases as dose increases; time to maximum blockade is up to 2 minutes longer with cisatracurium than with equipotent doses of atracurium.1 5

Good to excellent conditions for tracheal intubation occur within 1.5–2 or 1.5 minutes following IV dose of 0.15 or 0.2 mg/kg, respectively.1 5

Onset is faster in pediatric patients than in adults; also faster in infants than in older children.1 Onset may be delayed in geriatric patients compared with younger adults.1 16

In adults, doses of 0.15 or 0.2 mg/kg administered under balanced anesthesia produce maximum neuromuscular blockade in about 3.5 (range: 1.6–6.8) or 2.9 (range: 1.9–5.2) minutes, respectively.1 Maximum neuromuscular blockade after 0.1-mg/kg dose occurs about 1 minute later in geriatric patients than in younger adults.1

In children, doses of 0.1 or 0.15 mg/kg administered under balanced anesthesia produce maximum neuromuscular blockade in about 2.8 (range: 1.8–6.7) or 3 (range: 1.5–8) minutes, respectively.1 In infants, doses of 0.15 mg/kg administered under balanced anesthesia produce maximum neuromuscular blockade in about 2 minutes (range: 1.3–4.3).1

Duration

Intermediate duration of action.1 5 6 20 Duration of maximum neuromuscular blockade increases as the dose increases; when the cisatracurium dose is doubled, the clinically effective duration of blockade increases by approximately 25 minutes.1 Clinically effective duration of action and rate of spontaneous recovery with equipotent doses of cisatracurium and atracurium are similar.1

Duration is longer in adults than in pediatric patients; also longer in infants than in older children.1 No substantial difference in recovery profiles between geriatric and younger adults.1 11 16 Recovery following reversal is faster in children than in adults.1

In adults, clinically effective duration of neuromuscular blockade (i.e., time to 25% recovery) after dose of 0.15 or 0.2 mg/kg is 55 (range: 44–74) or 65 (range: 43–103) minutes, respectively.1

In children 2–12 years of age, clinically effective duration of neuromuscular blockade after dose of 0.1 or 0.15 mg/kg is approximately 28 (range: 21–38) or 36 (range: 29–46) minutes, respectively.1 In infants, clinically effective duration of neuromuscular blockade after dose of 0.15 mg/kg is approximately 43 minutes (range: 34–58 minutes).1

Duration of neuromuscular blockade induced by 0.03-mg/kg maintenance dose is approximately 20 minutes.1

In studies in patients receiving long-term (i.e., up to 6 days) infusion during mechanical ventilation, recovery of neuromuscular function (train-of-four ratio ≥70%) occurred in approximately 50 (range: 20–175) or 55 (range: 20–270) minutes following infusion discontinuance.1

Special Populations

In patients with end-stage liver disease, onset may be slightly faster; however, hepatic dysfunction does not substantially alter rate of recovery from neuromuscular blockade.1 3 6 16

In patients with renal failure, onset may be slightly delayed; however, renal dysfunction does not substantially alter rate of recovery from neuromuscular blockade.1 3 6 16

Gender and obesity not associated with substantial changes in predicted onset or rate of recovery.1 47

Distribution

Extent

Neuromuscular blocking agents generally distribute into extracellular fluid and rapidly reach site of action at motor end-plate of myoneural junction.2

Neuromuscular blocking agents may cross placenta.2

Volume of distribution of cisatracurium may be limited by its large molecular size and increased polarity.47 Higher steady-state volume of distribution when nontraditional two-compartment model of elimination is used compared with a one-compartment model.5 47

Plasma Protein Binding

Plasma protein binding cannot be determined because of rapid metabolism of cisatracurium.47 (See Elimination under Pharmacokinetics.)

Special Populations

Based on a one-compartment model, volume of distribution at steady-state may be increased in the elderly, ICU patients, and in patients with end-stage hepatic failure.5 6

In burn patients, possible increased protein binding (possibly to α1-acid glycoprotein) of neuromuscular blocking agents with subsequent decreases in the free fraction of circulating drug.33 34 35 37

Elimination

Metabolism

Rapidly metabolized via Hofmann elimination (independent of liver) to form a monoquaternary acrylate metabolite (which undergoes nonspecific plasma esterase hydrolysis and subsequent Hofmann elimination) and laudanosine (which is demethylated and glucuronidated).1 3 6 11 14 15 19 47 Both metabolites lack neuromuscular blocking activity; laudanosine may have CNS excitatory activity when present in large amounts.1 6 47

Rate of Hofmann elimination is dependent on temperature and pH.1 6 15

Elimination Route

Eliminated principally by Hofmann elimination (77–80%) and to lesser extent by renal and hepatic elimination (20%).1 6 Metabolites are eliminated principally by renal and hepatic elimination.1 Following administration of radiolabeled dose of cisatracurium to healthy individuals, 95% of administered dose is recovered in urine and 4% in feces; <10% of the dose is recovered as unchanged drug.1 6

Half-life

22–30 minutes.1 6 47

Special Populations

Patients with renal or hepatic dysfunction may exhibit longer half-lives; concentrations of metabolites after prolonged administration may be higher.1

Cisatracurium half-life may be slightly prolonged in geriatric patients.1 6

Pediatric patients may exhibit faster clearance of cisatracurium than adults.1

Stability

Storage

Parenteral

Injection

Original carton at 2–8°C; protect from light.1 Do not freeze.1

Use within 21 days once removed from refrigeration, regardless of whether injection was subsequently returned to refrigeration.1

Following dilution to final concentration of 0.1 mg/mL in 5% dextrose, 0.9% sodium chloride, or 5% dextrose and 0.9% sodium chloride injection, store at room temperature or refrigerate; use within 24 hours.1

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution CompatibilityHID

Compatible

Dextrose 5% in water

Dextrose 5% in sodium chloride 0.9%

Sodium chloride 0.9%

Incompatible

Ringer’s injection, lactated

Drug Compatibility
Y-Site CompatibilityHID

Compatible

Acyclovir sodium

Alfentanil HCl

Amikacin sulfate

Aztreonam

Bumetanide

Buprenorphine HCl

Butorphanol tartrate

Calcium gluconate

Ceftaroline fosamil

Ceftriaxone sodium

Chlorpromazine HCl

Ciprofloxacin

Clindamycin phosphate

Dexamethasone sodium phosphate

Dexmedetomidine HCl

Digoxin

Diphenhydramine HCl

Dobutamine HCl

Dopamine HCl

Doxycycline hyclate

Droperidol

Enalaprilat

Epinephrine HCl

Esmolol HCl

Famotidine

Fenoldopam mesylate

Fentanyl citrate

Fluconazole

Gentamicin sulfate

Haloperidol lactate

Hetastarch in lactated electrolyte injection (Hextend)

Hydrocortisone sodium succinate

Hydromorphone HCl

Hydroxyzine HCl

Imipenem-cilastatin sodium

Isoproterenol HCl

Lidocaine HCl

Linezolid

Lorazepam

Magnesium sulfate

Mannitol

Meperidine HCl

Metoclopramide HCl

Metronidazole

Midazolam HCl

Morphine sulfate

Nalbuphine HCl

Nitroglycerin

Norepinephrine bitartrate

Ondansetron HCl

Palonosetron HCl

Phenylephrine HCl

Potassium chloride

Procainamide HCl

Prochlorperazine edisylate

Promethazine HCl

Ranitidine HCl

Remifentanil HCl

Sufentanil citrate

Theophylline

Tobramycin sulfate

Vancomycin HCl

Zidovudine

Incompatible

Amphotericin B cholesteryl sulfate complex

Micafungin sodium

Variable

Acyclovir sodium

Aminophylline

Amphotericin B

Ampicillin sodium

Ampicillin sodium and sulbactam sodium

Cefazolin sodium

Cefotaxime sodium

Cefoxitin sodium

Ceftazidime

Cefuroxime sodium

Co-trimoxazole

Diazepam

Furosemide

Ganciclovir sodium

Heparin sodium

Ketorolac tromethamine

Methylprednisolone sodium succinate

Piperacillin sodium–tazobactam sodium

Propofol

Sodium bicarbonate

Sodium nitroprusside

Ticarcillin disodium-clavulanate potassium

Actions

  • Produces skeletal muscle relaxation by causing a decreased response to acetylcholine (ACh) at the myoneural (neuromuscular) junction of skeletal muscle.1 2

  • Exhibits high affinity for ACh receptor sites and competitively blocks access of ACh to motor end-plate of myoneural junction; may affect ACh release.1 2

  • Blocks the effects of both the small quantities of ACh that maintain muscle tone and the large quantities of ACh that produce voluntary skeletal muscle contraction; does not alter the resting electrical potential of the motor end-plate or cause muscular contractions.2

  • Neuromuscular blocking potency of cisatracurium is approximately threefold that of atracurium.1 7 14

  • Exhibits minimal, if any, cardiovascular effects.1 3 16 18 20

  • Exhibits little histamine-releasing activity at usual therapeutic doses.1 5 11 14 17 19

Advice to Patients

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1

  • Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses (e.g., cardiovascular disease, neuromuscular disease).1

  • Importance of informing patients of other important precautionary information.1 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Cisatracurium Besylate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

Injection, for IV use only

2 mg (of cisatracurium) per mL

Cisatracurium Besylate Injection

Nimbex

Abbvie

10 mg (of cisatracurium) per mL

Cisatracurium Besylate Injection

Nimbex

Abbvie

AHFS DI Essentials. © Copyright 2017, Selected Revisions October 23, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

1. Abbvie. Nimbex (cisatracurium besylate) injection prescribing information. North Chicago, IL; 2016 Dec.

2. AHFS Drug Information 2018. McEvoy GK, ed. Neuromuscular blocking agents general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2018.

3. Society of Critical Care Medicine and American Society of Health-System Pharmacists. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Am J Health-Syst Pharm. 2002; 59:179-95. [PubMed 11826571]

4. Society of Critical Care Medicine and American Society of Health-System Pharmacists. Sedation, analgesia, and neuromuscular blockade of the critically ill adult: revised clinical practice guidelines for 2002. Am J Health-Syst Pharm. 2002; 59:147-9. [PubMed 11826569]

5. Bryson HM, Faulds D. Cisatracurium besilate: a review of its pharmacology and clinical potential in anaesthetic practice. Drugs. 1997; 53:848-66. [PubMed 9129870]

6. Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet. 1999; 36:27-40. [PubMed 9989341]

7. Mellinghoff H, Radbruch L, Diefenbach C et al. A comparison of cisatracurium and atracurium: onset of neuromuscular block after bolus injection and recovery after subsequent infusion. Anesth Analg. 1996; 83:1072-5. [PubMed 8895288]

8. Newman PJ, Quinn AC, Grounds RM et al. A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients. Crit Care Med. 1997; 25:1139-42. [PubMed 9233738]

9. Pearson AJ, Harper NJ, Pollard BJ. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients. Intensive Care Med. 1996; 22:694-8. [PubMed 8844237]

10. Burmester M, Mok Q. Randomised controlled trial comparing cisatracurium and vecuronium infusions in a paediatric intensive care unit. Intensive Care Med. 2005; 31:686-92. [PubMed 15815895]

11. Melloni C, Devivo P, Launo C et al. Cisatracurium versus vecuronium: a comparative, double blind, randomized, multicenter study in adult patients under propofol/fentanyl/N2O anesthesia. Minerva Anestesiol. 2006; 72:299-308. [PubMed 16675938]

12. Searle NR, Thomson I, Dupont C et al. A two-center study evaluating the hemodynamic and pharmacodynamic effects of cisatracurium and vecuronium in patients under going coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 1999; 13:20-5. [PubMed 10069278]

13. Bion J, Prielipp RC, Bihari D et al. Cisatracurium in intensive care. Curr Opin Anaesthesiol. 1996; 9 (Suppl 1):S47-S51.

14. Prielipp RC, Coursin DB, Scuderi PE et al. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg. 1995; 81:3-12. [PubMed 7598277]

15. Cammu G, Coddens J, Hendrickx J et al. Dose requirements of infusions of cisatracurium or rocuronium during hypothermic cardiopulmonary bypass. Br J Anaesth. 2000; 84:587-90. [PubMed 10844834]

16. Cope TM, Hunter JM. Selecting neuromuscular-blocking drugs for elderly patients. Drugs Aging. 2003; 20:125-40. [PubMed 12534313]

17. Selcuk M, Celebioglu B, Celiker V et al. Infusion and bolus administration of cisatracurium: effects on histamine release. Middle East J Anesthesiol. 2005; 18:407-19. [PubMed 16438016]

18. Reich DL, Mulier J, Viby-Mogensen J et al. Comparison of the cardiovascular effects of cisatracurium and vecuronium in patients with coronary artery disease. Can J Anaesth. 1998; 45:794-7. [PubMed 9793671]

19. Doenicke A, Soukup J, Hoernecke R et al. The lack of histamine release with cisatracurium: a double-blind comparison with vecuronium. Anesth Analg. 1997; 84:623-8. [PubMed 9052314]

20. McManus MC. Neuromuscular blockers in surgery and intensive care, part 1. Am J Health-Syst Pharm. 2001; 58:2287-99. [PubMed 11763807]

21. McManus MC. Neuromuscular blockers in surgery and intensive care, part 2. Am J Health-Syst Pharm. 2001; 58: 2381-99. [PubMed 11794954]

22. Reynolds SF, Heffner J. Airway management of the critically ill patient: rapid-sequence intubation. Chest. 2005; 127:1397-412. DOI: 10.1378/chest.127.4.1397. [PubMed 15821222]

23. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006:217-36.

24. American Academy of Pediatrics Committee on Fetus and Newborn and Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. Pediatrics. 1983; 72:356 8. [PubMed 6889041]

25. Anon. Benzyl alcohol may be toxic to newborns. FDA Drug Bull. 1982; 12(2):10 11.

26. Centers for Disease Control. Neonatal deaths associated with use of benzyl alcohol. MMWR. 1982; 31:290 1. [PubMed 6810084]

27. Gershanik J, Boecler B, Ensley H et al. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med. 1982; 307:1384 8. [PubMed 7133084]

28. Menon PA, Thach BT, Smith CH et al. Benzyl alcohol toxicity in a neonatal intensive care unit: incidence, symptomatology, and mortality. Am J Perinatol. 1984; 1:288 92. [PubMed 6440575]

29. Anderson CW, Ng KJ, Andresen B et al. Benzyl alcohol poisoning in a premature newborn infant. Am J Obstet Gynecol. 1984; 148:344 6. [PubMed 6695984]

30. Richard A, Girard F, Girard DC et al. Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. Anesth Analg. 2005; 100:538-44. [PubMed 15673889]

31. Breslin DS, Jiao K, Habib AS et al. Pharmacodynamic interactions between cisatracurium and rocuronium. Anesth Analg. 2004; 98:107-10. [PubMed 14693597]

32. Hemmerling TM, Schuettler J, Schwilden H. Desflurane reduces the effective therapeutic infusion rate (ETI) of cisatracurium more than isoflurane, sevoflurane, or propofol. Can J Anaesth. 2001; 48:532-7. [PubMed 11444446]

33. Mills AK, Martyn JAJ. Evaluation of atracurium neuromuscular blockade in pediatric patients with burns. Br J Anaesth. 1988; 60:450-5. [PubMed 3355741]

34. Dwersteg JF, Pavlin EG, Heimbach DM. Patients with burns are resistant to atracurium. Anesthesiology. 1986; 65:517-20. [PubMed 3777482]

35. Marathe PH, Dwersteg JF, Pavlin EG et al. Effect of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans. Anesthesiology. 1989; 70:752-5. [PubMed 2719307]

36. Martyn J, Goldhill DR, Goudsouzian NG. Clinical pharmacology of muscle relaxants in patients with burns. J Clin Pharmacol. 1986; 26:680-5. [PubMed 2947935]

37. Anon. Neuromuscular blockers in patients with burns. Lancet. 1988; 2:1003-4. [PubMed 2902437]

38. Pavlin EG, Haschke RH, Marathe P et al. Resistance to atracurium in thermally injured rats: the roles of time, activity, and pharmacodynamics. Anesthesiology. 1988; 69:696-701. [PubMed 3189916]

39. Mills AK, Martyn AJ. Neuromuscular blockade with vecuronium in paediatric patients with burn injuries. Br J Clin Pharmacol. 1989; 28:155-9. [PubMed 2570602]

40. Pinard AM, Donati F, Martineau R et al. Magnesium potentiates neuromuscular blockade with cisatracurium during cardiac surgery. Can J Anesth. 2003; 50:172-8. [PubMed 12560310]

41. American Regent, Inc. Verapamil hydrochloride injection prescribing information. Shirley, NY; 2003 Jan.

42. Fodale V, Pratico C. Girlanda P et al. Acute motor axonal polyneuropathy after a cisatracurium infusion and concomitant corticosteroid therapy. Br J Anaesth. 2004; 92:289-93. [PubMed 14722188]

44. Vecuronium (eg, Norcuron) interactions: verapamil (eg, Calan). In: Hansten PD, Horn JR. Hansten and Horn’s drug interactions analysis and management. St Louis, MO: Wolters Kluwer Health; 2004:1012.

45. Kallet RH, Alonso JA, Luce JM et al. Exacerbation of acute pulmonary edema during assisted mechanical ventilation using a low-tidal volume, lung-protective ventilator strategy. Chest. 1999; 116:1826-32. [PubMed 10593817]

46. Arroliga A, Frutos-Vivar F, Hall J et al. Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest. 2005; 128:496-506. [PubMed 16100131]

47. Schmith VD, Phillips L, Kisor DF et al. Pharmacokinetics/pharmacodynamics of cisatracurium in healthy adult patients. Curr Opin Anaesthesiol. 1996; 9 (Suppl1):S9-S15.

48. Abbott Laboratories, Abbott park, IL: Personal communication.

355. Bevan DR, Donati F, Kopman AF. Reversal of neuromuscular blockade. Anesthesiology. 1992; 77:785-805. [PubMed 1416176]

356. Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth. 2009; 103:115-29. [PubMed 19468024]

357. Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesth Analg. 2010; 111:129-40. [PubMed 20442261]

358. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010; 111:120-8. [PubMed 20442260]

359. Institute for Safe Medication Practices. Paralyzed by mistakes: reassess the safety of neuromuscular blockers in your facility. ISMP Medication Safety Alert! Acute Care edition. Horsham, PA; 2016 June. From ISMP website

422. Claudius C, Garvey LH, Viby-Mogensen J. The undesirable effects of neuromuscular blocking drugs. Anaesthesia. 2009; 64 Suppl 1:10-21. [PubMed 19222427]

423. Murray MJ, DeBlock H, Erstad B et al. Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Crit Care Med. 2016; 44:2079-2103. [PubMed 27755068]

424. Hampton JP. Rapid-sequence intubation and the role of the emergency department pharmacist. Am J Health Syst Pharm. 2011; 68:1320-30. [PubMed 21719592]

HID. Trissel LA. Handbook on injectable drugs. 18th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2015:280-86.

Hide